243 related articles for article (PubMed ID: 32455942)
1. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.
Barile E; Baggio C; Gambini L; Shiryaev SA; Strongin AY; Pellecchia M
Molecules; 2020 May; 25(10):. PubMed ID: 32455942
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide bioinformatics analysis of human protease capacity for proteolytic cleavage of the SARS-CoV-2 spike glycoprotein.
Matveev EV; Ponomarev GV; Kazanov MD
Microbiol Spectr; 2024 Feb; 12(2):e0353023. PubMed ID: 38189333
[TBL] [Abstract][Full Text] [Related]
3. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
4. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
Belen-Apak FB; Sarialioglu F
Med Hypotheses; 2020 Sep; 142():109743. PubMed ID: 32335456
[TBL] [Abstract][Full Text] [Related]
5. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.
Liu H; Gai S; Wang X; Zeng J; Sun C; Zhao Y; Zheng Z
Cardiovasc Res; 2020 Aug; 116(10):1733-1741. PubMed ID: 32638018
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Spike Furin Cleavage Site and S2' Basic Residues Modulate the Entry Process in a Host Cell-Dependent Manner.
Lavie M; Dubuisson J; Belouzard S
J Virol; 2022 Jul; 96(13):e0047422. PubMed ID: 35678602
[TBL] [Abstract][Full Text] [Related]
7. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Romeo A; Iacovelli F; Falconi M
Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
[TBL] [Abstract][Full Text] [Related]
8. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.
Hoffmann M; Kleine-Weber H; Pöhlmann S
Mol Cell; 2020 May; 78(4):779-784.e5. PubMed ID: 32362314
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein.
Kleine-Weber H; Elzayat MT; Hoffmann M; Pöhlmann S
Sci Rep; 2018 Nov; 8(1):16597. PubMed ID: 30413791
[TBL] [Abstract][Full Text] [Related]
10. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
11. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
12. Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages.
Singh N; Decroly E; Khatib AM; Villoutreix BO
Eur J Pharm Sci; 2020 Oct; 153():105495. PubMed ID: 32730844
[TBL] [Abstract][Full Text] [Related]
13. Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease.
Stevaert A; Van Berwaer R; Mestdagh C; Vandeput J; Vanstreels E; Raeymaekers V; Laporte M; Naesens L
mBio; 2022 Aug; 13(4):e0137622. PubMed ID: 35913162
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells.
Bestle D; Heindl MR; Limburg H; Van Lam van T; Pilgram O; Moulton H; Stein DA; Hardes K; Eickmann M; Dolnik O; Rohde C; Klenk HD; Garten W; Steinmetzer T; Böttcher-Friebertshäuser E
Life Sci Alliance; 2020 Sep; 3(9):. PubMed ID: 32703818
[TBL] [Abstract][Full Text] [Related]
15. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
16. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways.
Laporte M; Raeymaekers V; Van Berwaer R; Vandeput J; Marchand-Casas I; Thibaut HJ; Van Looveren D; Martens K; Hoffmann M; Maes P; Pöhlmann S; Naesens L; Stevaert A
PLoS Pathog; 2021 Apr; 17(4):e1009500. PubMed ID: 33886690
[TBL] [Abstract][Full Text] [Related]
17. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
19. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
Kaur U; Chakrabarti SS; Ojha B; Pathak BK; Singh A; Saso L; Chakrabarti S
Curr Drug Targets; 2021; 22(2):192-201. PubMed ID: 32972339
[TBL] [Abstract][Full Text] [Related]
20. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
